Metropolitan Life Insurance Company (MetLife)’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-2,703
| Closed | -$39.7K | – | 1401 |
|
|
2024
Q1 | $39.7K | Hold |
2,703
| – | – | ﹤0.01% | 1523 |
|
|
2023
Q4 | $27.9K | Hold |
2,703
| – | – | ﹤0.01% | 1769 |
|
|
2023
Q3 | $21.2K | Hold |
2,703
| – | – | ﹤0.01% | 1865 |
|
|
2023
Q2 | $27K | Buy |
+2,703
| New | +$27K | ﹤0.01% | 1770 |
|
|
2023
Q1 | – | Sell |
-2,703
| Closed | -$29.7K | – | 2415 |
|
|
2022
Q4 | $29.7K | Hold |
2,703
| – | – | ﹤0.01% | 1797 |
|
|
2022
Q3 | $35.2K | Hold |
2,703
| – | – | ﹤0.01% | 1695 |
|
|
2022
Q2 | $34.2K | Buy |
2,703
+575
| +27% | +$7.29K | ﹤0.01% | 1734 |
|
|
2022
Q1 | $29.8K | Sell |
2,128
-6,891
| -76% | -$96.5K | ﹤0.01% | 1889 |
|
|
2021
Q4 | $261K | Hold |
9,019
| – | – | ﹤0.01% | 1829 |
|
|
2021
Q3 | $270K | Buy |
+9,019
| New | +$270K | ﹤0.01% | 1860 |
|
|
2021
Q2 | – | Sell |
-6,951
| Closed | -$216K | – | 2819 |
|
|
2021
Q1 | $216K | Buy |
6,951
+3,458
| +99% | +$108K | ﹤0.01% | 1967 |
|
|
2020
Q4 | $115K | Hold |
3,493
| – | – | ﹤0.01% | 2296 |
|
|
2020
Q3 | $122K | Buy |
+3,493
| New | +$122K | ﹤0.01% | 2105 |
|